Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy

Lance K. Lassiter, Mohan K. Tummala, Maha H. Hussain, Walter M. Stadler, Daniel P. Petrylak, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Background: Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multi-institutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. Patients and Methods: Eligible patients included those with bi-dimensionally measurable disease and an Eastern Cooperative Oncology Group performance status of 0-2, transitional cell carcinoma or adenocarcinoma of the urothelium, and nonresponse to ≥ 1 previous standard chemotherapy regimen. Patients received piritrexim orally at 25 mg 3 times daily (every 8 hours regularly) for 5 consecutive days each week for 3 weeks, followed by a 1-week rest period. Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. Results: Of the 23 patients enrolled, 19 patients and 22 patients were assessable for toxicity and response, respectively. Two patients required dose reduction because of toxicity, 2 patients discontinued study because of toxicity, and 6 patients had ≥ 1 serious adverse event. Except for grade 1/2 pain and fatigue, gastrointestinal toxicities were the most commonly reported events, followed by fever, delirium, and myelosuppression. No objective responses were observed, with 2 patients demonstrating stable disease after 2-4 cycles. By the statistical design of the trial, further enrollment was halted because of lack of activity. Conclusion: Regardless of modest side effects, oral piritrexim in heavily pretreated patients is inactive at this dose and schedule, confirming the results of a recent cooperative group trial.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalClinical Genitourinary Cancer
Volume6
Issue number1
DOIs
StatePublished - Mar 2008

Fingerprint

Urothelium
Carcinoma
Drug Therapy
piritrexim
Delirium
Transitional Cell Carcinoma
Fatigue

Keywords

  • Antineoplastic activity
  • Myelosuppression
  • Pyrimidines
  • Second-line therapy
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. / Lassiter, Lance K.; Tummala, Mohan K.; Hussain, Maha H.; Stadler, Walter M.; Petrylak, Daniel P.; Carducci, Michael A.

In: Clinical Genitourinary Cancer, Vol. 6, No. 1, 03.2008, p. 31-35.

Research output: Contribution to journalArticle

Lassiter, Lance K. ; Tummala, Mohan K. ; Hussain, Maha H. ; Stadler, Walter M. ; Petrylak, Daniel P. ; Carducci, Michael A. / Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. In: Clinical Genitourinary Cancer. 2008 ; Vol. 6, No. 1. pp. 31-35.
@article{6064e3bc01744489a7d7c6c6362f2020,
title = "Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy",
abstract = "Background: Piritrexim is reported to have a response rate of 38{\%} in patients with chemotherapy-naive disease and 23{\%} for second-line therapy after chemotherapy failure. We report the results of a multi-institutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. Patients and Methods: Eligible patients included those with bi-dimensionally measurable disease and an Eastern Cooperative Oncology Group performance status of 0-2, transitional cell carcinoma or adenocarcinoma of the urothelium, and nonresponse to ≥ 1 previous standard chemotherapy regimen. Patients received piritrexim orally at 25 mg 3 times daily (every 8 hours regularly) for 5 consecutive days each week for 3 weeks, followed by a 1-week rest period. Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. Results: Of the 23 patients enrolled, 19 patients and 22 patients were assessable for toxicity and response, respectively. Two patients required dose reduction because of toxicity, 2 patients discontinued study because of toxicity, and 6 patients had ≥ 1 serious adverse event. Except for grade 1/2 pain and fatigue, gastrointestinal toxicities were the most commonly reported events, followed by fever, delirium, and myelosuppression. No objective responses were observed, with 2 patients demonstrating stable disease after 2-4 cycles. By the statistical design of the trial, further enrollment was halted because of lack of activity. Conclusion: Regardless of modest side effects, oral piritrexim in heavily pretreated patients is inactive at this dose and schedule, confirming the results of a recent cooperative group trial.",
keywords = "Antineoplastic activity, Myelosuppression, Pyrimidines, Second-line therapy, Transitional cell carcinoma",
author = "Lassiter, {Lance K.} and Tummala, {Mohan K.} and Hussain, {Maha H.} and Stadler, {Walter M.} and Petrylak, {Daniel P.} and Carducci, {Michael A}",
year = "2008",
month = "3",
doi = "10.3816/CGC.2008.n.005",
language = "English (US)",
volume = "6",
pages = "31--35",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy

AU - Lassiter, Lance K.

AU - Tummala, Mohan K.

AU - Hussain, Maha H.

AU - Stadler, Walter M.

AU - Petrylak, Daniel P.

AU - Carducci, Michael A

PY - 2008/3

Y1 - 2008/3

N2 - Background: Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multi-institutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. Patients and Methods: Eligible patients included those with bi-dimensionally measurable disease and an Eastern Cooperative Oncology Group performance status of 0-2, transitional cell carcinoma or adenocarcinoma of the urothelium, and nonresponse to ≥ 1 previous standard chemotherapy regimen. Patients received piritrexim orally at 25 mg 3 times daily (every 8 hours regularly) for 5 consecutive days each week for 3 weeks, followed by a 1-week rest period. Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. Results: Of the 23 patients enrolled, 19 patients and 22 patients were assessable for toxicity and response, respectively. Two patients required dose reduction because of toxicity, 2 patients discontinued study because of toxicity, and 6 patients had ≥ 1 serious adverse event. Except for grade 1/2 pain and fatigue, gastrointestinal toxicities were the most commonly reported events, followed by fever, delirium, and myelosuppression. No objective responses were observed, with 2 patients demonstrating stable disease after 2-4 cycles. By the statistical design of the trial, further enrollment was halted because of lack of activity. Conclusion: Regardless of modest side effects, oral piritrexim in heavily pretreated patients is inactive at this dose and schedule, confirming the results of a recent cooperative group trial.

AB - Background: Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multi-institutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. Patients and Methods: Eligible patients included those with bi-dimensionally measurable disease and an Eastern Cooperative Oncology Group performance status of 0-2, transitional cell carcinoma or adenocarcinoma of the urothelium, and nonresponse to ≥ 1 previous standard chemotherapy regimen. Patients received piritrexim orally at 25 mg 3 times daily (every 8 hours regularly) for 5 consecutive days each week for 3 weeks, followed by a 1-week rest period. Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. Results: Of the 23 patients enrolled, 19 patients and 22 patients were assessable for toxicity and response, respectively. Two patients required dose reduction because of toxicity, 2 patients discontinued study because of toxicity, and 6 patients had ≥ 1 serious adverse event. Except for grade 1/2 pain and fatigue, gastrointestinal toxicities were the most commonly reported events, followed by fever, delirium, and myelosuppression. No objective responses were observed, with 2 patients demonstrating stable disease after 2-4 cycles. By the statistical design of the trial, further enrollment was halted because of lack of activity. Conclusion: Regardless of modest side effects, oral piritrexim in heavily pretreated patients is inactive at this dose and schedule, confirming the results of a recent cooperative group trial.

KW - Antineoplastic activity

KW - Myelosuppression

KW - Pyrimidines

KW - Second-line therapy

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=43249097245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249097245&partnerID=8YFLogxK

U2 - 10.3816/CGC.2008.n.005

DO - 10.3816/CGC.2008.n.005

M3 - Article

VL - 6

SP - 31

EP - 35

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -